Department of Biochemistry and Molecular Biology, College of Basic Medicine, China Medical University, Shenyang 110001, China.
Hum Pathol. 2011 Mar;42(3):424-33. doi: 10.1016/j.humpath.2009.12.018. Epub 2010 Dec 28.
Inhibitor of growth 5, a tumor suppressor protein, can interact with p53, thereby inhibiting cell growth and inducing apoptosis. Inhibitor of growth 5 overexpression results in a reduction in colony-forming efficiency and cell population in S phase. To clarify the roles of inhibitor of growth 5 in tumorigenesis and progression of colorectal carcinomas, we examined inhibitor of growth 5 expression by immunohistochemistry on a tissue microarray containing colorectal carcinomas (n = 306), adenomas (n = 69), and nonneoplastic mucosa (n = 288) and compared this with clinicopathologic parameters of the carcinomas. In addition, inhibitor of growth 5 expression in colorectal carcinoma tissues and cell lines (DLD-1, HCT-15, SW480, and WiDr) was analyzed by Western blot and reverse transcriptase-polymerase chain reaction. It was found that the inhibitor of growth 5 protein was localized to the nuclei of colon carcinoma cells with no differences at mRNA levels. Among 18 frozen samples of colorectal carcinoma, significantly increased expression of inhibitor of growth 5 protein was observed in the carcinoma in comparison with adjacent mucosa in 14 cases (77.8%; P < .05), and 71.4% (10/14) of carcinoma cases exhibited up-regulated inhibitor of growth 5 mRNA expression. Decreased inhibitor of growth 5 expression was detected by immunohistochemistry in colorectal carcinoma, compared with non-neoplastic mucosa and adenoma (P < .05). Nuclear inhibitor of growth 5 expression was negatively correlated with tumor size, depth of invasion, degree of dedifferentiation, and Union Internationale Contre le Cancer staging (P < .05). In contrast, cytoplasmic inhibitor of growth 5 expression was positively correlated with depth of invasion, lymphatic invasion, and Union Internationale Contre le Cancer staging (P < .05). It was suggested that aberrant inhibitor of growth 5 expression may contribute to pathogenesis, growth, and invasion of colorectal carcinomas and could be considered as a promising marker to gauge aggressiveness of colorectal carcinomas.
生长抑制剂 5 是一种肿瘤抑制蛋白,可与 p53 相互作用,从而抑制细胞生长并诱导细胞凋亡。生长抑制剂 5 的过表达导致集落形成效率和 S 期细胞群体减少。为了阐明生长抑制剂 5 在结直肠癌发生和进展中的作用,我们通过免疫组织化学方法在包含结直肠癌(n = 306)、腺瘤(n = 69)和非肿瘤性黏膜(n = 288)的组织微阵列上检测了生长抑制剂 5 的表达,并将其与癌的临床病理参数进行了比较。此外,还通过 Western blot 和逆转录聚合酶链反应分析了生长抑制剂 5 在结直肠癌组织和细胞系(DLD-1、HCT-15、SW480 和 WiDr)中的表达。结果发现,生长抑制剂 5 蛋白定位于结肠癌细胞的核内,mRNA 水平无差异。在 18 例结直肠癌的冷冻样本中,与相邻黏膜相比,14 例(77.8%;P <.05)癌组织中生长抑制剂 5 蛋白表达显著增加,且 71.4%(10/14)的癌组织中生长抑制剂 5 mRNA 表达上调。与非肿瘤性黏膜和腺瘤相比,结直肠癌中生长抑制剂 5 的免疫组织化学表达减少(P <.05)。核内生长抑制剂 5 表达与肿瘤大小、浸润深度、去分化程度和国际抗癌联盟分期呈负相关(P <.05)。相反,细胞质生长抑制剂 5 表达与浸润深度、淋巴浸润和国际抗癌联盟分期呈正相关(P <.05)。提示异常的生长抑制剂 5 表达可能有助于结直肠癌的发病机制、生长和侵袭,可作为评估结直肠癌侵袭性的有前途的标志物。